Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only

Novel adjuvants present a concern for adverse effects, generating a need for alternatives. Rotavirus inner capsid VP6 protein could be considered a potential candidate, due to its ability to self-assemble into highly immunogenic nanospheres and nanotubes. These nanostructures exhibit immunostimulatory properties, which resemble those of traditional adjuvants, promoting the uptake and immunogenicity of the co-administered antigens. We have previously elucidated an adjuvant effect of VP6 on co-delivered norovirus and coxsackievirus B1 virus-like particles, increasing humoral and cellular responses and sparing the dose of co-delivered antigens. This study explored an immunostimulatory effect of VP6 nanospheres on smaller antigens, P particles formed by protruding domain of a norovirus capsid protein and a short peptide, extracellular matrix protein (M2e) of influenza A virus. VP6 exhibited a notable improving impact on immune responses induced by P particles in immunized mice, including systemic and mucosal antibody and T cell responses. The adjuvant effect of VP6 nanospheres was comparable to the effect of alum, except for induction of superior mucosal and T cell responses when P particles were co-administered with VP6. However, unlike alum, VP6 did not influence M2e-specific immune responses, suggesting that the adjuvant effect of VP6 is dependent on the particulate nature of the co-administered antigen.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:8

Enthalten in:

Vaccines - 8(2020), 3 vom: 07. Juli

Sprache:

Englisch

Beteiligte Personen:

Heinimäki, Suvi [VerfasserIn]
Tamminen, Kirsi [VerfasserIn]
Hytönen, Vesa P [VerfasserIn]
Malm, Maria [VerfasserIn]
Blazevic, Vesna [VerfasserIn]

Links:

Volltext

Themen:

Adjuvant
Alum
Journal Article
M2e
Nanostructure
P particle
Peptide
VP6

Anmerkungen:

Date Revised 27.10.2020

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/vaccines8030365

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM312227760